DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
CN100386329C
(zh)
|
2002-06-06 |
2008-05-07 |
贝林格尔.英格海姆药物公司 |
取代的3-氨基-噻吩并[2,3-b]吡啶-2-羧酸酰胺化合物及其制备方法和用途
|
US7276519B2
(en)
|
2002-11-25 |
2007-10-02 |
Wyeth |
Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
|
US7202363B2
(en)
|
2003-07-24 |
2007-04-10 |
Abbott Laboratories |
Thienopyridine and furopyridine kinase inhibitors
|
CN101676285A
(zh)
|
2004-03-30 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
用作jak和其它蛋白激酶抑制剂的氮杂吲哚
|
GB0420722D0
(en)
*
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
US7777040B2
(en)
|
2005-05-03 |
2010-08-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
NZ592968A
(en)
|
2006-01-17 |
2012-08-31 |
Vertex Pharma |
Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
|
EP1987030B1
(en)
|
2006-02-17 |
2011-11-09 |
Pfizer Limited |
3 -deazapurine derivatives as tlr7 modulators
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
|
PE20080145A1
(es)
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
US7842713B2
(en)
|
2006-04-20 |
2010-11-30 |
Pfizer Inc |
Fused phenyl amido heterocyclic compounds
|
UA93548C2
(uk)
*
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
WO2007146602A1
(en)
|
2006-06-06 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
|
US8227603B2
(en)
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
KR101410453B1
(ko)
|
2006-08-02 |
2014-06-27 |
싸이토키네틱스, 인코포레이티드 |
소정의 화학 물질, 조성물 및 방법
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
JP5513118B2
(ja)
|
2006-10-19 |
2014-06-04 |
シグナル ファーマシューティカルズ,エルエルシー |
ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
|
CN101678022A
(zh)
|
2006-12-21 |
2010-03-24 |
弗特克斯药品有限公司 |
可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
|
WO2008092860A1
(en)
*
|
2007-01-30 |
2008-08-07 |
Janssen Pharmaceutica N.V. |
Bicyclic derivatives as ep4 agonists
|
WO2008092861A1
(en)
*
|
2007-01-30 |
2008-08-07 |
Janssen Pharmaceutica N.V. |
Bicyclic derivatives as ep4 agonists
|
WO2008092862A1
(en)
*
|
2007-01-30 |
2008-08-07 |
Janssen Pharmaceutica N.V. |
Bicyclic derivatives as ep4 agonists
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
RS52978B
(en)
*
|
2007-03-20 |
2014-02-28 |
Curis, Inc. |
FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
|
EP2139478A4
(en)
|
2007-03-30 |
2010-05-05 |
Cytokinetics Inc |
CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
EP2162445B1
(en)
|
2007-06-05 |
2013-11-27 |
Takeda Pharmaceutical Company Limited |
Heterobicyclic compounds as kinase inhibitors
|
US8324395B2
(en)
|
2007-08-23 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
UA100126C2
(en)
|
2007-09-14 |
2012-11-26 |
Аддекс Фарма С.А. |
1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
|
JP5433579B2
(ja)
|
2007-09-14 |
2014-03-05 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド. |
1,3−二置換−4−フェニル−1h−ピリジン−2−オン
|
PT2200985E
(pt)
|
2007-09-14 |
2011-07-21 |
Ortho Mcneil Janssen Pharm |
4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
|
TW200920369A
(en)
|
2007-10-26 |
2009-05-16 |
Amira Pharmaceuticals Inc |
5-lipoxygenase activating protein (flap) inhibitor
|
CN101861316B
(zh)
|
2007-11-14 |
2013-08-21 |
奥梅-杨森制药有限公司 |
咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
JP5562865B2
(ja)
|
2007-12-17 |
2014-07-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
|
CA2713864A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions and methods
|
US7998976B2
(en)
*
|
2008-02-04 |
2011-08-16 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
WO2009100333A2
(en)
*
|
2008-02-06 |
2009-08-13 |
Senomyx, Inc. |
Sweetener compositions and methods of making them
|
MX2010012814A
(es)
|
2008-05-23 |
2010-12-20 |
Amira Pharmaceuticals Inc |
Inhibidor de proteina activadora de 5-lipoxigenasa.
|
KR20110039307A
(ko)
|
2008-08-05 |
2011-04-15 |
다이이찌 산쿄 가부시키가이샤 |
이미다조피리딘-2-온 유도체
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
AU2009289784B2
(en)
|
2008-09-02 |
2012-03-22 |
Addex Pharma S.A. |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
TWI389913B
(zh)
*
|
2008-09-08 |
2013-03-21 |
Lg Life Sciences Ltd |
并合雜環化合物
|
AU2009290474A1
(en)
|
2008-09-11 |
2010-03-18 |
Pfizer Inc. |
Heteroaryls amide derivatives and their use as glucokinase activators
|
US8546431B2
(en)
|
2008-10-01 |
2013-10-01 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
RU2517181C2
(ru)
|
2008-10-16 |
2014-05-27 |
Орто-Макнейл-Янссен Фармасьютикалз, Инк. |
Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
PE20100362A1
(es)
*
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
BRPI0921333A2
(pt)
|
2008-11-28 |
2015-12-29 |
Addex Pharmaceuticals Sa |
derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
|
JP5579619B2
(ja)
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
MX2011005943A
(es)
|
2008-12-05 |
2011-06-27 |
Abbott Lab |
Derivados de tieno[3,2-c]piridina como inhibidores de cinasa para utilizarse en el tratamiento de cancer.
|
CA2786715C
(en)
*
|
2009-01-16 |
2019-05-21 |
Curis, Inc. |
Fused amino pyridines for the treatment of brain tumors
|
SI2406253T1
(sl)
|
2009-03-11 |
2013-09-30 |
Pfizer Inc. |
Derivati benzofuranila, uporabljeni kot inhibitorji glukokinaze
|
BRPI1010831A2
(pt)
*
|
2009-05-12 |
2016-04-05 |
Addex Pharmaceuticals Sa |
derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
KR101753826B1
(ko)
|
2009-05-12 |
2017-07-04 |
얀센 파마슈티칼즈, 인코포레이티드 |
1,2,4―트리아졸로[4,3―a]피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
|
DK2440558T3
(en)
|
2009-06-08 |
2015-07-06 |
Takeda Pharmaceutical |
Dihydropyrrolnaphthyridinon-relations as inhibitors of jak
|
NZ619259A
(en)
|
2009-06-17 |
2015-07-31 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
EP2442649A4
(en)
*
|
2009-06-19 |
2013-04-03 |
Astrazeneca Ab |
USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIALIZERS TO REDUCE NICOTINE DEPENDENCE
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
KR101147550B1
(ko)
|
2009-10-22 |
2012-05-17 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
|
WO2011053518A1
(en)
|
2009-10-26 |
2011-05-05 |
Signal Pharmaceuticals, Llc |
Methods of synthesis and purification of heteroaryl compounds
|
US8759359B2
(en)
*
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
TW201130842A
(en)
*
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
JP5816678B2
(ja)
|
2010-04-14 |
2015-11-18 |
インサイト・コーポレイションIncyte Corporation |
PI3Kδ阻害剤としての縮合誘導体
|
AR082453A1
(es)
|
2010-04-21 |
2012-12-12 |
Novartis Ag |
Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
|
CN103221411B
(zh)
|
2010-05-17 |
2016-05-11 |
富瑞姆制药公司 |
(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
MX2013003913A
(es)
|
2010-10-08 |
2013-09-26 |
Abbvie Inc |
Compuestos de furo [3, 2-d] pirimidina.
|
ES2536433T3
(es)
|
2010-11-08 |
2015-05-25 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
|
AU2011328203B2
(en)
|
2010-11-08 |
2015-03-19 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
EP2649069B1
(en)
|
2010-11-08 |
2015-08-26 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
CN103492381A
(zh)
|
2010-12-16 |
2014-01-01 |
沃泰克斯药物股份有限公司 |
流感病毒复制的抑制剂
|
AR084366A1
(es)
|
2010-12-20 |
2013-05-08 |
Incyte Corp |
N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
|
WO2012087833A1
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Hepatitis c inhibitors and uses thereof
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
CN103748085A
(zh)
|
2011-06-09 |
2014-04-23 |
诺华股份有限公司 |
杂环磺酰胺衍生物
|
JP6145451B2
(ja)
|
2011-07-08 |
2017-06-14 |
ノバルティス アーゲー |
新規なピロロピリミジン誘導体
|
EA028060B1
(ru)
|
2011-07-13 |
2017-10-31 |
Сайтокинетикс, Инк. |
Комбинированная терапия бокового амиотрофического склероза
|
US8436179B2
(en)
|
2011-07-20 |
2013-05-07 |
Abbvie Inc. |
Kinase inhibitor with improved solubility profile
|
RU2631482C2
(ru)
|
2011-07-22 |
2017-09-22 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Композиция
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
HUE043703T2
(hu)
|
2011-09-02 |
2019-09-30 |
Incyte Holdings Corp |
Heterociklusos aminok PI3K inhibitorokként
|
CA2850617A1
(en)
|
2011-10-03 |
2013-04-11 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
EA034512B1
(ru)
|
2011-10-19 |
2020-02-14 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Лечение злокачественной опухоли ингибиторами tor-киназы
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
ES2406635B1
(es)
*
|
2011-12-02 |
2014-06-11 |
Cartonajes Bernabeu, S.A. |
Sistema paletizador para lineas de alimentacion de embalajes.
|
ES2411804B1
(es)
*
|
2011-12-02 |
2014-05-12 |
Universidad De Zaragoza |
Compuestos inhibidores de la agregación del péptido beta amiloide.
|
BR112014013332B1
(pt)
|
2011-12-02 |
2022-09-06 |
Signal Pharmaceuticals, Llc |
Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
|
AU2013202305B2
(en)
|
2012-02-24 |
2015-03-12 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
AU2013259871A1
(en)
|
2012-05-08 |
2014-11-20 |
Forum Pharmaceuticals Inc. |
Methods of maintaining, treating or improving cognitive function
|
WO2013177168A1
(en)
|
2012-05-22 |
2013-11-28 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
CN107383009B
(zh)
|
2012-06-13 |
2020-06-09 |
因塞特控股公司 |
作为fgfr抑制剂的取代的三环化合物
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
AU2013305790B2
(en)
|
2012-08-24 |
2016-09-08 |
Glaxosmithkline Llc |
Pyrazolopyrimidine compounds
|
EP2909211A4
(en)
|
2012-10-17 |
2016-06-22 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
KR20150085080A
(ko)
|
2012-11-20 |
2015-07-22 |
글락소스미스클라인 엘엘씨 |
신규 화합물
|
US9428512B2
(en)
|
2012-11-20 |
2016-08-30 |
Glaxosmithkline Llc |
Compounds
|
ES2639789T3
(es)
|
2012-11-20 |
2017-10-30 |
Glaxosmithkline Llc |
Compuestos novedosos
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
US9771330B2
(en)
|
2012-11-27 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
AU2013365926B9
(en)
|
2012-12-21 |
2019-01-17 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
AU2014207641A1
(en)
|
2013-01-16 |
2015-08-06 |
Signal Pharmaceuticals, Llc |
Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
|
KR101446680B1
(ko)
|
2013-02-08 |
2014-10-07 |
한국과학기술연구원 |
mGluR1 길항제로 작용하는 사이에노피리미디논 유도체
|
MX2015010714A
(es)
|
2013-02-19 |
2016-06-14 |
Pfizer |
Compuestos de azabencimidazol.
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
CN105392499B
(zh)
|
2013-04-17 |
2018-07-24 |
西格诺药品有限公司 |
用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
|
EP2986322A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
CN105324381A
(zh)
|
2013-04-17 |
2016-02-10 |
西格诺药品有限公司 |
有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
|
NZ629411A
(en)
|
2013-04-17 |
2017-06-30 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
ES2944478T3
(es)
|
2013-04-17 |
2023-06-21 |
Signal Pharm Llc |
1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
|
MX2015014455A
(es)
|
2013-04-17 |
2016-07-21 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
|
AU2014254058B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
|
CN105263931B
(zh)
|
2013-04-19 |
2019-01-25 |
因赛特公司 |
作为fgfr抑制剂的双环杂环
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
CA3143529A1
(en)
|
2013-05-29 |
2014-12-04 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
WO2014199195A1
(en)
|
2013-06-11 |
2014-12-18 |
Latvian Institute Of Organic Synthesis |
THIENO[2,3-b]PYRIDINES AS MULTIDRUG RESISTANCE MODULATORS
|
CA2915561C
(en)
|
2013-06-21 |
2020-09-22 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
EA035601B1
(ru)
|
2013-06-21 |
2020-07-14 |
Зенит Эпидженетикс Лтд. |
Бициклические ингибиторы бромодомена
|
CN105593224B
(zh)
|
2013-07-31 |
2021-05-25 |
恒元生物医药科技(苏州)有限公司 |
作为溴结构域抑制剂的新型喹唑啉酮类化合物
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
TWI648281B
(zh)
|
2013-10-17 |
2019-01-21 |
日商安斯泰來製藥股份有限公司 |
含硫二環式化合物
|
CN105849100B
(zh)
|
2013-11-13 |
2019-07-16 |
沃泰克斯药物股份有限公司 |
流感病毒复制抑制剂
|
CA2930297C
(en)
|
2013-11-13 |
2022-04-05 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing inhibitors of influenza viruses replication
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
US9108953B2
(en)
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
MX2016009471A
(es)
|
2014-01-21 |
2016-10-13 |
Janssen Pharmaceutica Nv |
Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
|
HUE045610T2
(hu)
|
2014-01-21 |
2020-01-28 |
Janssen Pharmaceutica Nv |
2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
|
CA2937431A1
(en)
|
2014-01-29 |
2015-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds
|
WO2015113451A1
(en)
|
2014-01-29 |
2015-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds
|
AU2015244179A1
(en)
|
2014-04-11 |
2016-11-03 |
The University Of North Carolina At Chapel Hill |
Mertk-specific pyrrolopyrimidine compounds
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
ES2823756T3
(es)
|
2014-04-16 |
2021-05-10 |
Signal Pharm Llc |
Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
EP3134405B1
(en)
|
2014-04-25 |
2019-08-28 |
Pfizer Inc |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
EA201790189A1
(ru)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
|
JP6713982B2
(ja)
|
2014-07-24 |
2020-06-24 |
ファイザー・インク |
ピラゾロピリミジン化合物
|
MX2017001565A
(es)
|
2014-08-06 |
2017-04-27 |
Pfizer |
Compuestos de imidazopiridazina.
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
EP3227281A4
(en)
|
2014-12-01 |
2018-05-30 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
CA2966449A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
EP3233846A4
(en)
|
2014-12-17 |
2018-07-18 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
EP3617205B1
(en)
|
2015-02-20 |
2021-08-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
TWI764392B
(zh)
|
2015-02-27 |
2022-05-11 |
美商英塞特公司 |
Pi3k抑制劑之鹽及製備方法
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
JP6857617B2
(ja)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤
|
JP6704416B2
(ja)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤を調製する方法
|
KR101816233B1
(ko)
*
|
2015-10-29 |
2018-01-08 |
삼성에스디아이 주식회사 |
유기 광전자 소자용 화합물, 유기 광전자 소자 및 표시 장치
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
WO2017207340A1
(de)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
MX2019002212A
(es)
|
2016-08-24 |
2019-07-08 |
Arqule Inc |
Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos.
|
WO2018060072A1
(de)
|
2016-09-29 |
2018-04-05 |
Bayer Pharma Aktiengesellschaft |
Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
WO2018060174A1
(de)
|
2016-09-29 |
2018-04-05 |
Bayer Pharma Aktiengesellschaft |
Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
|
CN110337437B
(zh)
|
2016-12-28 |
2023-02-03 |
达特神经科学有限公司 |
作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CN110996955A
(zh)
|
2017-06-22 |
2020-04-10 |
细胞基因公司 |
以乙型肝炎病毒感染为特征的肝细胞癌的治疗
|
JP7254078B2
(ja)
|
2017-11-27 |
2023-04-07 |
ダート・ニューロサイエンス・エルエルシー |
Pde1阻害剤としての置換フラノピリミジン化合物
|
JP2021523118A
(ja)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
Fgfr阻害剤の塩
|
US11466004B2
(en)
|
2018-05-04 |
2022-10-11 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
TW202016076A
(zh)
*
|
2018-05-31 |
2020-05-01 |
南韓商C&C新藥研究所 |
雜環衍生物及其用途
|
RS65335B1
(sr)
|
2018-10-05 |
2024-04-30 |
Annapurna Bio Inc |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
|
CN113874015B
(zh)
|
2018-12-21 |
2024-05-24 |
细胞基因公司 |
Ripk2的噻吩并吡啶抑制剂
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
US11358971B2
(en)
|
2019-07-03 |
2022-06-14 |
H. Lundbeck A/S |
Prodrugs of modulators of the NMDA receptor
|
US11466027B2
(en)
|
2019-07-03 |
2022-10-11 |
H. Lundbeck A/S |
Modulators of the NMDA receptor
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
AU2020366006A1
(en)
|
2019-10-14 |
2022-04-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
WO2021133915A1
(en)
*
|
2019-12-23 |
2021-07-01 |
Sanford Burnham Prebys Medical Discovery Institute |
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
EP4146639A1
(en)
|
2020-05-06 |
2023-03-15 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
KR20230012597A
(ko)
|
2020-05-19 |
2023-01-26 |
칼리오페, 인크. |
Ampk 활성화제
|
JP2023531726A
(ja)
|
2020-06-26 |
2023-07-25 |
キャリーオペ,インク. |
Ampkアクチベーター
|
KR20230104781A
(ko)
|
2020-10-05 |
2023-07-10 |
인라이븐 테라퓨틱스, 인크. |
Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式ヘテロ環
|
WO2023086319A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|